Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. (NYSE: PFE) announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VTX-801, Vivet’s clinical-stage gene therapy for the treatment of Wilson Disease – a rare, genetic disorder that reduces the ability of the liver and other tissues to regulate copper levels, causing severe hepatic damage, neurological symptoms, and potentially death.
VTX-801 receives U.S. FDA Fast Track designation for the treatment of Wilson Disease
August 13, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022